Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07108023 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hematological Disorders in EHPVO Patients

Study acronym: EHPVO-HEM
StatusNot Yet Recruiting
PhaseNot specified
SponsorRahab Nady
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 6, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Study First Submitted
This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver. This blockage can cause problems like an enlarged spleen, bleeding from swollen veins in the digestive system, and low blood cell counts. Many of these patients may have hidden blood disorders that increase the risk of clotting, such as myeloproliferative neoplasms (MPNs), antiphospholipid syndrome (APS), or paroxysmal nocturnal hemoglobinuria (PNH). This study will collect and analyze blood test results-such as complete blood count (CBC), liver function tests (LFTs), and clotting tests-from patients with EHPVO. The aim is to find patterns that may suggest an underlying blood disorder, even if the patient doesn't show obvious symptoms.By understanding these patterns early, doctors may be able to diagnose and treat the root causes of clotting in these patients more accurately, helping prevent complications and improve outcomes.
Trial Details
NCT Number NCT07108023
Lead Sponsor Rahab Nady
Conditions
(from sponsor)
Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia, Myeloproliferative Neoplasms (MPN), Antiphospholipid Syndrome (APS), Paroxysmal Nocturnal Hemoglobinuria (PNH), Thrombocytopenia, Anemia, Leukopenia
Related terms Anemia, Antiphospholipid Syndrome, Hematologic Diseases, Hemoglobinuria, Paroxysmal, Hypersplenism, Leukopenia, Myeloproliferative Disorders, Thrombocytopenia, Thrombophilia
Enrollment 115 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov